問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Ophthalmology

Division of General Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

Taipei Veterans General Hospital

更新時間：2023-09-19

陳達慶Chen, Ta-Ching
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

  • taiwanirdproject@gmail.com

Recruiting Trial

36Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳達慶

List

49Cases

2024-09-01 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-01-01 - 2027-12-31

Phase III

Active
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  • Condition/Disease

    Gastric Cancer /Gastroesophageal Junction Cancer

  • Test Drug

    AZD0901

Participate Sites
7Sites

Recruiting7Sites

2021-12-01 - 2032-12-31

Phase III

Active
A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    TAGRISSO Film-coated Tablets 40 mg/ TAGRISSO Film-coated Tablets 80 mg

Participate Sites
8Sites

Recruiting8Sites

2025-11-01 - 2031-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2022-12-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-09-15 - 2025-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2024-11-01 - 2029-08-31

Phase III

Active
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    N/A

Participate Sites
10Sites

Recruiting10Sites

2024-12-01 - 2031-05-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-05-01 - 2028-07-31

Phase II

Active
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Subjects with Metastatic Colorectal Cancer (AndroMETa-CRC-533)

  • Condition/Disease

    Metastatic colorectal cancer (mCRC)

  • Test Drug

    ABBV-400

Participate Sites
6Sites

Recruiting6Sites

2023-04-22 - 2026-10-30

Phase III

Active
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

  • Condition/Disease

    Geographic Atrophy

  • Test Drug

    錠劑

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB